The Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Aarey Drugs & Pharmaceuticals to clarify discrepancies found in the XBRL filing of its financial results for the quarter ended 31-December-2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. This is a routine compliance query related to how the numbers were reported electronically rather than the underlying financials themselves. The company's response is still awaited. No penalty or adverse action has been announced yet.
For now, this is a minor procedural compliance flag with no immediate impact on shareholders or stock price. Investors should watch for the company's clarification; if unresolved, it could lead to further regulatory scrutiny or trading restrictions.